Articles & Press Releases

How Value-Based Contracts Are Redefining Drug Pricing Through Clinical Trials

The pharmaceutical industry is increasingly moving towards value-based contracts (VBCs), where drug pricing is tied to real-world patient outcomes rather than traditional volume-based models. This shift is transforming how clinical trials are designed and executed, and it’s profoundly impacting drug pricing strategies.

How Gene Therapies Are Reshaping Patient Outcomes and Payer Expectations

Gene therapies are redefining modern healthcare, offering the potential to address the root causes of genetic disorders through targeted treatment rather than symptom management. For patients, this represents a profound improvement in quality of life, while for payers and pharmaceutical companies, gene therapies introduce new challenges in contract structuring, reimbursement, and financial planning. In this blog, we’ll explore how gene therapies are reshaping patient outcomes, impacting payer expectations, and how Lyfegen’s solutions, such as the Agreements Library and Drug Contracting Simulator, are enabling pharma and payers to navigate this evolving landscape.

The role of value-based care in patient access

With rising healthcare costs around the world, value-based care (VBC) is a paradigm shift poised to make healthcare more accessible and affordable. It’s a departure from the traditional fee-for-service (FFS) model, which pays providers each time they perform a service. In this type of care model, providers are rewarded for the volume of care they provide, rather than the quality.

Drug Market Access Strategies in 2024: Key Considerations for Pharma Companies

The pharmaceutical industry and its drug market access strategies are continuing to evolve as we move through 2024, driven by mounting pricing pressures, aggressive regulatory shifts, and heightened payer demands. For pharma companies, refining market access strategies is no longer optional—it’s essential to securing rapid market entry and sustained patient access in an increasingly challenging environment. Let’s explore the key considerations for pharma companies within this space.

The Joint Clinical Assessment (JCA): A New Era for Market Access Strategies in the EU

The Joint Clinical Assessment (JCA) is poised to fundamentally change how health technologies gain market access across the European Union. Designed to streamline the evaluation process, the JCA promises to bring greater consistency, transparency, and efficiency to how new therapies and medical technologies are assessed for clinical effectiveness. But what does this mean for your market access strategies?

Lyfegen erhält 8 Millionen Dollar, um Arzneimittelpreise zu senken und Patienten den Zugang zu lebensrettenden Medikamenten zu erleichtern

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

We are thrilled to welcome Ina Hasani to our team at Lyfegen as Director of Sales & Business Development for Canada. Ina brings nearly a decade of experience in the life sciences sector, specializing in healthcare strategy, market access, and health economics. We sat down with Ina to learn more about her background, her vision for transforming healthcare in Canada, and what excites her most about joining Lyfegen.

A Fable of the Blue Bird and Lyfegen's Wise Owls

Once upon a time, In a whimsical forest, there lived a smart and creative blue bird. This bird, known for its brilliance in the world of tiny forest biotech, had concocted a magical potion.

Driving Growth: Welcoming Our New VP of Sales & Business Development, Simon Farrow

Amid the buzz of innovation at Lyfegen, we sat down with Simon, our newest team member, whose journey has brought a fresh...

Driving Growth: Welcoming Our New VP of Sales & Business Development, Simon Farrow

Amid the buzz of innovation at Lyfegen, we sat down with Simon, our newest team member, whose journey has brought a fresh perspective to our mission.

Amid the buzz of innovation at Lyfegen, we sat down with Simon, our newest team member, whose journey has brought a fresh...

Exclusive interview with Girisha Fernando at the launch of Lyfegen’s Value-Based Agreement Library

At this years World Evidence, Pricing and Access event, Girisha Fernando, the CEO of Lyfegen, expressed excitement as he spoke about the company’s latest launched offering - the Lyfegen Model & Agreement Library. This unique learning resource is a true game-changer that builds upon the company’s existing product. It expands our horizons by allowing payers and market access & pricing professionals to explore over 2’500 real-life public agreements, and 18 drug pricing models from around the world. The library provides an unparalleled understanding of drug reimbursement models that help users make better informed choices like never before.

The Tech Team Keeps Growing! Welcome to the Lyfegen Team, Analytical-Superstar, Pavlo!

He’s analytical, a techie and has a fantastic gift for music! Yes, we are talking about the latest addition to our team, our very own “Technical Business Analyst” and Ukrainian superstar: Pavlo Lupandin!

The Cost of Innovation: Budget Impact of Gene Therapy for Sickle Cell Disease on Medicaid Plans

In December 2023, the U.S. Food and Drug Administration (FDA) approved two groundbreaking gene therapies for sickle cell disease (SCD), offering a new lease on life for individuals battling this severe condition. However, while these therapies bring significant clinical improvements, their cost has emerged as a formidable challenge, particularly for Medicaid, which covers approximately half of the 100,000 individuals in the U.S. with SCD.

Linking Drug Prices to Success: The Power of Outcome-Based Agreements in the Ozempic Era

Outcome-Based Contracts (OBAs) are set to revolutionize access to high-demand medications by linking drug prices to patient outcomes. Specifically, this model ensures that the cost of medication reflects its real-world effectiveness, thereby encouraging better healthcare and sustainable pharmaceutical spending. As outcome-based healthcare gains momentum, OBAs will further push pharmaceutical companies to focus on developing innovative, effective treatments rather than just boosting sales. GLP-1 drugs, such as Wegovy and Ozempic, which are popular for weight loss, could exemplify this shift.

Study: Out-of-pocket drug costs increasing 5.8% per year

A new study investigated how drug rebates affect out-of-pocket costs for health plan beneficiaries. Rebates lower costs for payers, but depending on the health plan, they can raise costs for the patient.

Ongoing debate around GLP-1 drug coverage

Payers are seeing increased costs due to the demand of GLP-1 drugs. It’s estimated that 57.4 million adults under the age of 65 could be eligible for this class of drugs, based on currently approved FDA indications. There are 36.2 million people with an obesity diagnosis alone in the US.

Study: Approval-to-reimbursement times in the US vs. Europe

A new study published in September, reported by the American Journal of Managed Care, compared how quickly drugs are reimbursed in select countries, including Switzerland, the United States, Germany, Japan, and the United Kingdom. The US does not have an HTA process, and some believe that drugs could get to patients faster if it did have one.

All the insights you need in one place.

On-Demand Insights

Rewriting the Playbook: How AI Can Accelerate Market Access & Pricing Decisions

2024 in Review: Are Drug Access Agreement Trends Going the Right Way?

Revolutionizing Drug Access in Portugal: Scaling Outcome-Based Agreements with Digital Innovation

Innovative Rebate Management in Oncology Drug Budgets

Articles & Press Releases

How Value-Based Contracts Are Redefining Drug Pricing Through Clinical Trials

How Value-Based Contracts Are Redefining Drug Pricing Through Clinical Trials

How Gene Therapies Are Reshaping Patient Outcomes and Payer Expectations

How Gene Therapies Are Reshaping Patient Outcomes and Payer Expectations

The role of value-based care in patient access

The role of value-based care in patient access

Drug Market Access Strategies in 2024: Key Considerations for Pharma Companies

Drug Market Access Strategies in 2024: Key Considerations for Pharma Companies

The Joint Clinical Assessment (JCA): A New Era for Market Access Strategies in the EU

The Joint Clinical Assessment (JCA): A New Era for Market Access Strategies in the EU

Lyfegen erhält 8 Millionen Dollar, um Arzneimittelpreise zu senken und Patienten den Zugang zu lebensrettenden Medikamenten zu erleichtern

Lyfegen erhält 8 Millionen Dollar, um Arzneimittelpreise zu senken und Patienten den Zugang zu lebensrettenden Medikamenten zu erleichtern

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

A Fable of the Blue Bird and Lyfegen's Wise Owls

A Fable of the Blue Bird and Lyfegen's Wise Owls

Driving Growth: Welcoming Our New VP of Sales & Business Development, Simon Farrow

Driving Growth: Welcoming Our New VP of Sales & Business Development, Simon Farrow

Exclusive interview with Girisha Fernando at the launch of Lyfegen’s Value-Based Agreement Library

Exclusive interview with Girisha Fernando at the launch of Lyfegen’s Value-Based Agreement Library

The Tech Team Keeps Growing! Welcome to the Lyfegen Team, Analytical-Superstar, Pavlo!

The Tech Team Keeps Growing! Welcome to the Lyfegen Team, Analytical-Superstar, Pavlo!

The Cost of Innovation: Budget Impact of Gene Therapy for Sickle Cell Disease on Medicaid Plans

The Cost of Innovation: Budget Impact of Gene Therapy for Sickle Cell Disease on Medicaid Plans

Linking Drug Prices to Success: The Power of Outcome-Based Agreements in the Ozempic Era

Linking Drug Prices to Success: The Power of Outcome-Based Agreements in the Ozempic Era

Study: Out-of-pocket drug costs increasing 5.8% per year

Study: Out-of-pocket drug costs increasing 5.8% per year

Ongoing debate around GLP-1 drug coverage

Ongoing debate around GLP-1 drug coverage

Study: Approval-to-reimbursement times in the US vs. Europe

Study: Approval-to-reimbursement times in the US vs. Europe

All the insights you need in one place.

On-Demand Insights

Rewriting the Playbook: ​ How AI Can Accelerate Market Access & Pricing Decisions​

2024 in Review: Are Drug Access Agreement Trends Going the Right Way?

Revolutionizing Drug Access in Portugal: Scaling Outcome-Based Agreements with Digital Innovation

Innovative Rebate Management in Oncology Drug Budgets

Articles & Press Releases

How Value-Based Contracts Are Redefining Drug Pricing Through Clinical Trials

How Value-Based Contracts Are Redefining Drug Pricing Through Clinical Trials

How Gene Therapies Are Reshaping Patient Outcomes and Payer Expectations

How Gene Therapies Are Reshaping Patient Outcomes and Payer Expectations

The role of value-based care in patient access

The role of value-based care in patient access

Drug Market Access Strategies in 2024: Key Considerations for Pharma Companies

Drug Market Access Strategies in 2024: Key Considerations for Pharma Companies

The Joint Clinical Assessment (JCA): A New Era for Market Access Strategies in the EU

The Joint Clinical Assessment (JCA): A New Era for Market Access Strategies in the EU

Lyfegen erhält 8 Millionen Dollar, um Arzneimittelpreise zu senken und Patienten den Zugang zu lebensrettenden Medikamenten zu erleichtern

Lyfegen erhält 8 Millionen Dollar, um Arzneimittelpreise zu senken und Patienten den Zugang zu lebensrettenden Medikamenten zu erleichtern

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

Transforming Healthcare Access in Canada: Ina Hasani’s Vision at Lyfegen

A Fable of the Blue Bird and Lyfegen's Wise Owls

A Fable of the Blue Bird and Lyfegen's Wise Owls

Driving Growth: Welcoming Our New VP of Sales & Business Development, Simon Farrow

Driving Growth: Welcoming Our New VP of Sales & Business Development, Simon Farrow

Exclusive interview with Girisha Fernando at the launch of Lyfegen’s Value-Based Agreement Library

Exclusive interview with Girisha Fernando at the launch of Lyfegen’s Value-Based Agreement Library

The Tech Team Keeps Growing! Welcome to the Lyfegen Team, Analytical-Superstar, Pavlo!

The Tech Team Keeps Growing! Welcome to the Lyfegen Team, Analytical-Superstar, Pavlo!

The Cost of Innovation: Budget Impact of Gene Therapy for Sickle Cell Disease on Medicaid Plans

The Cost of Innovation: Budget Impact of Gene Therapy for Sickle Cell Disease on Medicaid Plans

Linking Drug Prices to Success: The Power of Outcome-Based Agreements in the Ozempic Era

Linking Drug Prices to Success: The Power of Outcome-Based Agreements in the Ozempic Era

Study: Out-of-pocket drug costs increasing 5.8% per year

Study: Out-of-pocket drug costs increasing 5.8% per year

Ongoing debate around GLP-1 drug coverage

Ongoing debate around GLP-1 drug coverage

Study: Approval-to-reimbursement times in the US vs. Europe

Study: Approval-to-reimbursement times in the US vs. Europe

Rewriting the Playbook: How AI Can Accelerate Market Access & Pricing Decisions